BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20172322)

  • 1. Evaluation of late immunologic parameters among renal transplant recipients induced with Campath-1H.
    Alba A; Morales J; Fierro A; Zehnder C; Cao C; Orozco R; Herzog C; Calabrán L; Contreras L; Buckel E
    Transplant Proc; 2010; 42(1):253-6. PubMed ID: 20172322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.
    Ruggenenti P; Perico N; Gotti E; Cravedi P; D'Agati V; Gagliardini E; Abbate M; Gaspari F; Cattaneo D; Noris M; Casiraghi F; Todeschini M; Cugini D; Conti S; Remuzzi G
    Transplantation; 2007 Oct; 84(8):956-64. PubMed ID: 17989600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
    Baez Y; Giron F; Niño-Murcia A; Rodríguez J; Salcedo S
    Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
    Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of Campath-1H as induction therapy in renal transplantation: preliminary results.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roohipour R; Carreno MR; Roth D; Ruiz P; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2004 Aug; 78(3):426-33. PubMed ID: 15316372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory T cells and T cell depletion: role of immunosuppressive drugs.
    Noris M; Casiraghi F; Todeschini M; Cravedi P; Cugini D; Monteferrante G; Aiello S; Cassis L; Gotti E; Gaspari F; Cattaneo D; Perico N; Remuzzi G
    J Am Soc Nephrol; 2007 Mar; 18(3):1007-18. PubMed ID: 17287424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A; Grego K; Bren AF
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection.
    Gill JS; Landsberg D; Johnston O; Shapiro RJ; Magil AB; Wu V; Tinckam K; Keown P
    Transplantation; 2010 Jan; 89(2):178-84. PubMed ID: 20098280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.
    Bloom DD; Chang Z; Fechner JH; Dar W; Polster SP; Pascual J; Turka LA; Knechtle SJ
    Am J Transplant; 2008 Apr; 8(4):793-802. PubMed ID: 18261176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of HLA disparity, immunosuppressive regimen used, and type of kidney allograft on production of anti-HLA class-I antibodies after transplant and occurrence of rejection.
    Abdelnoor AM; Ajib R; Chakhtoura M; Daouk M; Medawar W; Uwaydah M; Sawah SI; Khauli RB
    Immunopharmacol Immunotoxicol; 2009; 31(1):83-7. PubMed ID: 18752168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
    Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
    Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocyte-mediated acute renal rejection after combined treatment with preoperative Campath-1H (alemtuzumab) and postoperative immunosuppression.
    Zhang PL; Malek SK; Prichard JW; Lin F; Yahya TM; Schwartzman MS; Latsha RP; Skaletsky M; Norfolk ER; Brown RE; Hartle JE; Potdar S
    Ann Clin Lab Sci; 2004; 34(2):209-13. PubMed ID: 15228236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction with basiliximab in renal transplantation.
    Ferrer F; Machado S; Alves R; Macário F; Bastos C; Roseiro A; Mota A
    Transplant Proc; 2010 Mar; 42(2):467-70. PubMed ID: 20304166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Annual trends and triple therapy--1991-2000.
    Nishikawa K; Terasaki PI
    Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.